Articles Tagged With: vasomotor
-
Nonhormonal Treatment for Menopausal Vasomotor Symptoms: A Phase III Study of Fezolinetant
In this multinational, randomized, double blind, placebo-controlled trial, 522 women with moderate to severe menopausal vasomotor symptoms received either 45 mg of fezolinetant, 30 mg fezolinetant, or placebo. Both fezolinetant doses significantly reduced the frequency and severity of menopausal symptoms at four and 12 weeks of treatment as compared with placebo.
-
Ripples From Original WHI Study Results Continue: Is This Appropriate?
Recommendations for menopausal hormone therapy were widely publicized and adopted following the original publication of the results of the Women’s Health Initiative and affected both initiation and continuation of estrogen therapy through at least 2013.
-
Counsel women on how to cope with menopause’s vasomotor symptoms
New research indicates that frequent vasomotor symptoms associated with menopause could last more than seven years for many women.